You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Maria Luigia Randi + 2870 word(s) 2870 2021-12-14 03:56:53 |
2 format correct Bruce Ren Meta information modification 2870 2022-01-24 02:01:19 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Randi, M.L. Essential Thrombocythemia in Children and Adolescents. Encyclopedia. Available online: https://encyclopedia.pub/entry/18617 (accessed on 05 December 2025).
Randi ML. Essential Thrombocythemia in Children and Adolescents. Encyclopedia. Available at: https://encyclopedia.pub/entry/18617. Accessed December 05, 2025.
Randi, Maria Luigia. "Essential Thrombocythemia in Children and Adolescents" Encyclopedia, https://encyclopedia.pub/entry/18617 (accessed December 05, 2025).
Randi, M.L. (2022, January 21). Essential Thrombocythemia in Children and Adolescents. In Encyclopedia. https://encyclopedia.pub/entry/18617
Randi, Maria Luigia. "Essential Thrombocythemia in Children and Adolescents." Encyclopedia. Web. 21 January, 2022.
Essential Thrombocythemia in Children and Adolescents
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers13236147

ET is a rare disease in children, challenging pediatric and adult hematologists alike. The current WHO classification acknowledges classical Philadelphia-negative MPNs and defines diagnostic criteria, mainly encompassing adult cases. The presence of one of three driver mutations (JAK2V617F, CALR, and MPL mutations) represent the proof of clonality typical of ET. Pediatric ET cases are thus usually confronted by adult approaches. These can fit only some patients, because only 25–40% of cases present one of the driver mutations. The diagnosis of hereditary, familial thrombocytosis and the exclusion of reactive/secondary thrombocytosis must be part of the diagnostic process in children and can clarify most of the negative cases. Still, many children present a clinical, histological picture of ET, with a molecular triple wild-type status. Moreover, prognosis seems more benign, and thrombotic events are rare in children with ET and only minor hemorrhages are ordinarily observed.

pediatric myeloproliferative neoplasms thrombocytosis ET diagnosis ET treatment

1. Introduction

Essential thrombocythemia (ET), one of the Ph-negative Chronic Myeloproliferative neoplasms (MPNs), develops as an acquired clonal defect of myeloid precursor cells driving uncontrolled myeloid proliferation [1]. MPNs are characterized by elevated blood cell counts, with every lineage being distinctive to the various entities, albeit with some degree of overlapping. Within MPN, ET is characterized by high platelet counts, a finding which can also be found in polycythemia vera (PV), myelofibrosis (MF) and chronic myeloid leukemia (CML) [2]. Diagnosis of ET as well as of other MPNs has long been addressed by adult hematology and was recently confirmed within the WHO classification of myeloid neoplasm [3][4], gaining from the insight given by the identification of driver mutations and peculiar histological patterns (Table 1).
Table 1. WHO diagnostic criteria for essential thrombocytemia. Diagnosis of ET requires all 4 major criteria or the first 3 major criteria and the minor criterion to be met [3]. Thrombocytosis should be re-evaluated within at least 1 month.

MAJOR CRITERIA

1.     Platelet count ≥≥ 450 × 109/L

2.Bone marrow biopsy showing proliferation, mainly of the megakaryocyte lineage, with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant increase or left shift in neutrophil granulopoiesis or erythropoiesis and very rarely minor (grade 1) increase in reticulin fibers.

3.Not meeting WHO criteria for BCR ABL1+ CML, PV,

4.MF, myelodysplastic syndromes, or other myeloid neoplasms.

5.Presence of JAK2, CALR or MPL mutations.

MINOR CRITERION

Presence of a clonal marker or absence of evidence of reactive thrombocytosis.
ET is a rare disease in middle–advanced age and is even rarer in children [5]. Diagnosis and treatment of this clonal condition in pediatrics face both certainties and many dilemmas. First, the definition of thrombocytosis has been the matter of debate in children, because differences in platelets counts are seen in various ages and only a few studies have analyzed the issue. In fact, 30% of neonates and infants show high values, especially in the case of low-weight babies, [6][7]; an upper limit of 600 × 109 is considered normal in these children [8][9]. In older children and adolescents, the upper normal limit (95 percentile) of 450,000 has been identified [10], as suggested by the Italian Association for Pediatric Haematology Oncology (AIEOP) guidelines [11] and by other classifications of thrombocytosis [12]. Nonetheless, transient conditions and secondary reactive thrombocytosis are very common findings in pediatrics and require a thorough approach even when clear causes cannot be identified. The classical partition between primary and secondary/reactive thrombocytosis does not apply straightforwardly to children. Moreover, a third category of hereditary or familial thrombocytosis (HT) is unique to young age and must be ruled out [13]. Only in recent years has interest been focused on pediatric primary thrombocytosis and, in particular, on ET. Some papers [14][15][16][17][18] suggest that ET in children is different than in adults, with lower incidences of thrombotic and hemorrhagic complications and scarce or no evolution into myelofibrosis and acute leukemia. This poses questions regarding the opportunity of adapting the available hematological and management criteria to pediatric patients.

2. Hereditary/Familial Thrombocytosis (HT)

Hereditary and familial thrombocytosis are extremely rare. They share the same clinical aspects of primary thrombocytosis, comprising splenomegaly and the risk of thrombotic complications. Most of them have a Mendelian inheritance, are polyclonal and only affect the platelet lineage [13][19][20]. Affected genes are usually TPO or more frequently, its receptor c-MPL; gain of function mutations in the TPO gene have been described [21] and result in the proliferation of megakaryocytes, the activation of platelets and the significant overexpression of membrane molecules [22]. A founder effect found in families from Central Italy might explain the different percentages of non-clonal cases in Giona’s series [23].

3. Reactive/Secondary Thrombocytosis (ST)

Many children have transitorily increased platelet counts, mostly related to inflammatory conditions (Table 2). Therefore, an isolated finding of thrombocytosis is usually not clinically relevant in children. In contrast, if thrombocytosis is confirmed over at least 3–6 months, it may have a different pathogenesis and clinical impact [12][15].
Table 2. Causes of reactive/secondary thrombocytosis in children (adapted from [18]). The Table reports examples of significant pediatric conditions.
Infections
Inflammations
  • Kawasaki disease
  • Rheumatic diseases
  • Coeliac disease
  • Nephritis, pancreatitis
Surgery, trauma, burns, blood loss
Malignancies
Anemias
  • Iron deficiency
  • Hemolytic anemias
Allergic reactions
Drugs
  • Steroids
  • Vincristine
  • Miconazole
  • Antibiotics (Imipenem, Beta-lactams)
Megakaryopoiesis is controlled by various growth factors and cytokines. By far, the most essential growth factor is thrombopoietin (TPO), which is produced constitutively by the liver [24], but also by marrow stromal cells and by the kidney. TPO intervenes both in stem cell differentiation and in all stages of megakaryocytes maturation [25], through the binding to its receptor c-MPL and the activation of kinases of proliferative pathways (JAK, STAT1, STAT2, PI3K and MAPK). Its production is regulated by the bulk of circulating platelets and of marrow megakaryocytes.
Hepatic TPO mRNA expression is increased with inflammation [26]. Moreover, many interleukins (IL) involved in the inflammation processes, mostly IL-6 and IL-11, can stimulate the platelet production in the liver [27][28]. These processes are highly active during childhood: ST is reported in 6–15% of hospitalized children, and up to 1% of children in intensive care units show platelet counts exceeding 1000 × 109/L [5][29][30][31][32][33][34][35].
Infections, both bacterial and viral, are common causes of thrombocytosis in infants (75% of cases [31]), and children (47% [33]), mostly of the respiratory and urinary tracts. All other pediatric inflammatory conditions are associated with ST [34], in particular those seen in young children, such as Kawasaki disease [36], Schoenlein–Henoch syndrome, coeliac disease as well as rheumatic diseases and damages to tissues due to trauma, surgery or burns [8]. Many neoplasms (including acute leukemias) are also described to cause ST as well as chemotherapeutic drugs, steroids or adrenaline. Iron deficiency is a known cause of ST (5–12% [37]), although its precise mechanisms remain to be elucidated. Studies on megakaryocytes demonstrated that iron is essential for their proliferation as for other cells [38], and iron replacement resolves thrombocytosis [39].
The clinical relevance of ST is still debated. Platelet count can be regarded as an “acute phase” reactant [40], and has been shown to correlate with prognosis, mainly the prolongation of hospital staying. Most authors agree that ST is a collateral effect of the underlying disease and does not represent a risk for the patient. In fact, neither thrombotic nor hemorrhagic complications were seen in more than 4000 reported children with ST [32]. In 855 children affected by extreme thrombocytosis, Thom et al. reported 22 thromboses, all related to underlying conditions, and no hemorrhages [33].
Finally, asplenic patients commonly display an increased platelet count. Splenic atrophy or agenesia are extremely rare conditions, while splenectomies are performed in a wide spectrum of hematologic disorders: hereditary and autoimmune hemolytic diseases, thrombocytopenia, myeloproliferative diseases, leukemias and lymphomas [41], and a splenectomy could also be necessary after trauma [42]. Thrombocytosis tends to reduce within 6–12 months after splenectomy, sometimes never resolving. It has been shown that the thrombotic risk is likewise related to the underlying condition; in particular, it is higher in the case of lymphomas and myeloproliferative disorders, as well as in hereditary spherocytosis (HS) [41]. The use of antiaggregant therapy or other prophylactic measures are therefore to be used according to the primitive diagnosis, not only to the platelet count. In conclusion, ST does not usually require treatment, and the platelet count alteration usually normalizes with the resolution of the causal disease. Children with persistent thrombocytosis, but without any recognizable cause, should be investigated for the possible diagnosis of primary clonal or familial condition.

4. Essential Thrombocythemia (ET)

In ET (also commonly assumed as primary thrombocytosis), the increase in platelet count depends on a clonal disease of the bone marrow. These forms were grouped as myeloproliferative diseases and were later considered myeloproliferative neoplasms by the 2016 WHO classification [3][4] and comprise different entities, such as BCR-ABL-positive chronic myeloid leukemia, chronic eosinophilic leukemia, mastocytosis, some myelodysplastic syndromes, and the three entities within BCR-ABL-negative chronic MPN, i.e., ET, PV and MF. Thrombocytosis is the main hematological feature in ET, which, albeit typical of advanced age, is the most common MPN of childhood [5][6][7][8]. ET has an estimated incidence of 1 per 10 million annually [5]. However, ET is now recognized more frequently than in the past and an incidence of 0.6/100,000/year has been reported in children and young people under the age of 20 [43], probably due to the increased number of automated blood counts performed in children [18], and case series, not only case reports, have been published in recent years [8][15][16][17][18][43][44].

5. Managing Thrombocythemia in Children

Therapeutic guidelines for adults with ET are aimed to prevent vascular complications without increasing the risk of transformation [45]. Therefore, disease management is based on the risk stratification for thrombosis that has been internationally validated [46][47]. High risk factors, such as >60 age and a previous thrombotic event, are irrelevant or rare in children [48]. Thus, an identical risk-stratified strategy does not fit completely. To borrow from the experience gained with adults, ET represents a questionable option, also considering the different frequency of driver mutations and the high number of 3NEG, non-clonal cases in children in comparison to adults.
Few studies evaluating the best clinical approach to children with ET exist and, currently, only suggestions or guidelines based on experiences are published [12][18][35][44]. Moreover, any pharmacological treatment should theoretically be administered for a long time, or even for life. Long-term effects on growth, fertility and possible transformation must be weighed against all other options.
In 2015, the Italian Association for Pediatric Haematology Oncology (AIEOP) developed consensus-driven guidelines for diagnosis and treatment, available online [11]. Interestingly, even before the description of CALR mutations, those guidelines and criteria fit the most recent indications of Tefferi and Barbui [49]. The main criterion was to avoid any unnecessary drug administration: the initial aggressive therapeutic approach that was historically seen in many children (47% of Italian patients and most of the cases reported before 2008) has been changed. In asymptomatic children, a wait-and-watch approach is considered the best managing option. This requires careful, strict hematological and clinical observation, and so far (with a follow up of 3 to 30 years), no further complications have been described in our series. On the other hand, any thrombosis is a major event for children: would it be better to avoid any deep thrombosis rather than intervening after its occurrence? Moreover, the ability of anti-aggregation or cytoreduction to prevent major thrombosis in a child is still largely unknown.
Certainly, behavioral, familial or constitutional risk factors such as smoking, obesity, hyperlipemia and diabetes (as well as pregnancy [50]) need to be weighted in the final decision.

5.1. Antiaggregating Agents

Over the years, the efficacy of low-dose Acetylsalicylic acid (ASA) in PV [51] induced a wide use of similar treatments in ET, and low-dose aspirin is commonly used in adults with MPN [52]. However, a recent paper showed that the cardiovascular prophylaxis with 100 mg of aspirin appears inadequate in reducing platelet activation in most ET patients, which questions the classically used dosage [53]. Different schedules (BID/TID) are suggested for resistant symptoms [54].
Microvascular symptoms are common in pediatric ET and can be very disturbing. ASA can be used to control headache or erythromelalgia and doses can be tapered to the minimum according to efficacy. In fact, 1 mg/kg is usually effective for the control of symptoms. Caution is to be used in case of infection by varicella-zoster and influenza virus (for the possibility of hepatotoxicity and Reye syndrome). Moreover, the frequent observation of acquired von Willebrand (VW) disease, especially with extreme platelet counts (>1500 × 109/L), presents hemorrhagic risk. However, it is a common observation in our pediatric series that very high platelet counts are better tolerated by children and adolescents, with a low frequency of even minor hemorrhages.
Antiaggregating agents are suggested for low-risk, JAK2-mutated adult ET. Since, in our experience, JAK2 mutation is also associated with microvascular symptoms and at times major thrombosis, this recommendation can also be used for pediatric ET. It may be helpful to monitor VW ristocetin cofactor activity levels, which should be >20%, and high molecular weight multimers [55].

5.2. Anticoagulants

The use of anticoagulants is suggested in both adults and children with deep vein thrombosis. A recent systematic review of antithrombotic treatments adopted in patients with MPN and a history of VTE showed that direct oral anticoagulants (DOACs) and vitamin K antagonist (VKA) have a comparable, relatively low risk of recurrent thrombosis and bleeding events [56]. In addition, recent guidance suggests the use of DOACs for the treatment of splanchnic thromboses in non-cirrhotic patients in the absence of severe liver dysfunction [57]. Venous thromboembolism (VTE) is, fortunately, extremely rare in children with ET, but some cases of Budd–Chiari syndrome and cerebral sinus thromboses have been reported [58][59]. Approved anticoagulant drugs and management strategies in children with VTE have been reviewed recently [60]. The Einstein-Jr phase 3 study shows that body-weight-adjusted Rivaroxaban provides appropriate treatment for children with VTE [61].

5.3. Cytoreductive Drugs

The recommendations from the European Leukemia Net (ELN) reserve cytoreductive drugs for intermediate/high-risk patients with ET [45]. Hydroxyurea (HU) and interferon-alpha (IFN-a) or pegylated IFN alpha (Peg-IFNa) are considered first-line therapies for ET at any age. Initially, cytoreductive drugs such as HU, anagrelide and IFN-a were quite commonly used in thrombocythemic children even in the absence of high-risk factors. Careful analysis of the literature and of the national experiences led to a more careful, risk-adapted therapy. Therefore, high-risk children who have already experienced a thrombotic event (usually the first event leading to diagnosis) need cytoreduction, together with the addition of antithrombotic drugs [60]. Cytoreduction can be also considered in the case of low-risk ET children with resistant vascular symptoms and/or bleeding tendencies under ASA therapy [11][44][62][48]. In these cases, the reduced number of platelets to be obtained is still unknown.
Because the necessary duration of cytoreduction is unknown—yet probably very long—the histological modification of bone marrow and cytogenetical analysis should be monitored periodically in young patients undergoing cytoreduction.
There exists insufficient clinical data to recommend a specific agent in children. Moreover, no clear preference emerges among the available drugs. In the cases that need it, individually tailored treatment must be adopted. The child and the parents must be informed about the risk/benefit ratio of each choice, both interventional and observational, with a clear and thorough discussion regarding the possible long-lasting adverse effect of drugs adopted for therapy. Therefore, efforts should be made to summon prospective collaborative studies to evaluate types of drugs, duration and endpoints of treatment for ET in children.

5.3.1. Hydroxyurea (HU)

HU is usually considered the first-line treatment for any MPN and is usually the benchmark to confront any other available drug [63]. HU requires chronic oral administration and is generally well-tolerated. Its major concern is the possible risk of inducing transformation into acute leukemia [64]. This, however, has not definitively been ascertained. Experience suggests that HU is efficient and safe in young adults with ET [65] and that it does not induce adverse effects on growth and fertility when used in children with sickle-cell anemia [66]. However, HU might have different (and detrimental) effects in lifelong treatment for patients with a clonal diseases such as ET.

5.3.2. Interferon-Alpha (IFN-a)

IFN-a has been used since many years, but only with the introduction of its pegylated form has its side effects become more acceptable. IFN-a is capable of reducing platelet count; it is not leukemogenic nor teratogenic. PEG-IFN-a has been shown to be effective in PV resistant to HU [67][68], but results regarding ET are still controversial [69]. The possible ability of IFN-a to induce molecular and histological remission has encouraged its use [70][71].
Recently, a series of 13 children and young adults, six ET and seven PV, has been reported, where Peg-IFN-a has obtained acceptable results, with eight patients still on treatment. However, three complications were observed, and five patients discontinued treatment. Some collateral effects persist, including intolerance but also lack of complete response, and in three cases major complications were the reasons for discontinuation. Three cases showed a reduction in JAK2V617F allele burden [44].

5.3.3. Anagrelide

Anagrelide, a nonchemotherapeutic cytoreductive drug, is an alternative to HU. It is tolerable in the long-term, but anemia occurs in about 25% of patients, and it has been suggested that it could decrease the myelofibrosis-free survival [63][72]. However, Anagrelide in adult patients with ET has been considered useful and suitable for the prevention of thrombotic complications [73]. Therefore, it has also recently been widely used in younger patients [74] and was successful mainly in children poorly compliant to HU or IFN-a.

5.4. JAK2-Inhibitors

Ruxolitinib is the first developed JAK2 inhibitor, mainly used for MF and recently approved for HU-resistant PV [69][75]. In children, there exist some experiences in different conditions such as post-transplant graft versus host disease [76], and dose-finding studies have been carried out in pediatric neoplasms [77]. One infant with JAK2-positive polycythemia and Budd–Chiari syndrome was treated with success [78].

References

  1. Fialkow, P.J.; Faguet, G.B.; Jacobson, R.J.; Vaidya, K.; Murphy, S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981, 58, 916–919.
  2. Barbui, T.; Thiele, J.; Tefferi, A. Myeloproliferative neoplasms. N. Engl. J. Med. 2017, 377, 894–895.
  3. Arber, D.A.; Orazi, A.; Hesperian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127, 2391–2405.
  4. Barbui, T.; Thiele, J.; Gisslinger, H.; Kvasnicka, H.M.; Vannucchi, A.M.; Guglielmelli, P.; Orazi, A.; Tefferi, A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion. Blood Cancer J. 2018, 8, 15.
  5. Hasle, H. Incidence of essential trombocytemia in children. Br. J. Haematol. 2000, 110, 751.
  6. Dame, C.; Sutor, A.H. Primary and secondary thrombocytosis in childhood. Br. J. Haematol. 2005, 129, 165–177.
  7. Matsubara, K.; Fukaya, T.; Nigami, H.; Harigaya, H.; Hirata, T.; Nozaki, H.; Baba, K. Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta Haematol. 2004, 111, 132–137.
  8. Hofmann, I. Myeloproliferative neoplasms in children. J. Hematop. 2015, 8, 143–157.
  9. Orkin, S.; David, G.; Nathan, D.G.; Nathan, D. Nathan and Oski’s Hematology of Infancy and Childhood; Saunders: Philadelphia, PA, USA, 2008.
  10. Biino, G.; Santimone, I.; Minelli, C.; Sorice, R.; Frongia, B.; Traglia, M.; Ulivi, S.; Di Castelnuovo, A.; Gögele, M.; Nutile, T.; et al. Age-and sex-related variations in platelet count in Italy: A proposal of reference ranges based on 40987 subjects’ data. PLoS ONE 2013, 8, e54289.
  11. AIEOP Raccomandazioni per la Gestione Delle Trombocitosi in età Pediatrica. 2015. Available online: https://www.aieop.org/web/operatori-sanitari/linee-guida-consensum/ (accessed on 2 December 2021).
  12. Harrison, C.N.; Bareford, D.; Butt, N.; Campbell, P.; Conneally, E.; Drummond, M.; Erber, W.; Everington, T.; Green, A.R.; Hall, G.W.; et al. British Committee for standards in haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br. J. Haematol. 2010, 149, 352–375.
  13. Teofili, L.; Giona, F.; Martini, M.; Cenci, T.; Guidi, F.; Torti, L.; Palumbo, G.; Amendola, A.; Leone, G.; Foà, R.; et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007, 110, 3384–3386.
  14. Randi, M.L.; Putti, M.C.; Scapin, M.; Pacquola, E.; Tucci, F.; Micalizzi, C.; Zanesco, L.; Fabris, F. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006, 108, 3600–3602.
  15. Randi, M.L.; Geranio, G.; Bertozzi, I.; Micalizzi, C.; Ramenghi, U.; Tucci, F.; Notarangelo, L.D.; Ladogana, S.; Menna, G.; Giordano, P.; et al. Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort. Br. J. Haematol. 2015, 169, 584–589.
  16. Giona, F.; Teofili, L.; Moleti, M.L.; Martini, M.; Palumbo, G.; Amendola, A.; Mazzucconi, M.G.; Testi, A.M.; Pignoloni, P.; Orlando, S.M.; et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: Clinical and biologic features, treatment, and long-term outcome. Blood 2012, 119, 2219–2227.
  17. Fu, R.; Zhang, L.; Yang, R. Paediatric essential thrombocythaemia: Clinical and molecular features, diagnosis and treatment. Br. J. Haematol. 2013, 163, 295–302.
  18. Kucine, N.; Chastain, K.M.; Mahler, M.B.; Bussel, J.B. Primary thrombocytosis in children. Haematologica 2014, 99, 620–628.
  19. Teofili, L.; Giona, F.; Torti, L.; Cenci, T.; Ricerca, B.M.; Rumi, C.; Nunes, V.; Foà, R.; Leone, G.; Martini, M.; et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 2010, 95, 65–70.
  20. Teofili, L.; Larocca, L.M. Advances in understanding of the pathogenesis of familial thrombocythemia. Br. J. Haematol. 2011, 152, 701–712.
  21. Ghilardi, N.; Wiestner, A.; Kikuchi, M.; Osaka, A.; Skoda, R.C. Hereditary thrombocythemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br. J. Haematol. 1999, 107, 310–316.
  22. Wiestner, A.; Schempler, R.J.; van der Maas, A.P.; Scoda, R.C. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocytosis. Nat. Genet. 1998, 18, 49–52.
  23. Liu, K.; Martini, M.; Rocca, B.; Amos, C.I.; Teofili, L.; Giona, F.; Ding, J.; Komatsu, H.; Larocca, L.M.; Skoda, R.C. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica 2009, 94, 1368–1374.
  24. Sungarian, R.; Markovich, B.; Chong, B.H. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood 1997, 89, 101–107.
  25. Kaushansky, K. Thrombopoietina and its receptor in normal and neoplastic hematopoiesis. Thromb. J. 2016, 14, 40.
  26. Wolber, E.M.; Fandrey, J.; Frackowski, U.; Jelkmann, W. Hepatic thrombopoietin mRNAis increased in acute infections. Br. J. Haematol. 2002, 116, 612–618.
  27. Tefferi, A.; Ho, T.C.; Ahmann, G.J.; Katzmann, J.A.; Greipp, P.R. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am. J. Med. 1994, 97, 374–378.
  28. Wolber, E.M.; Jelkmann, W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J. Interferon Cytokine Res. 2000, 20, 499–506.
  29. Garoufi, A.; Voutsioti, K.; Tsapra, H.; Karpathios, T.; Zeis, P.M. Reactive thrombocytosis in children with upper urinary tract infections. Acta Paediatr. 2001, 90, 448–449.
  30. Indolfi, G.; Catania, P.; Bartolini, E.; Azzari, C.; Massai, C.; Poggi, G.M.; De Martino, M.; Resti, M. Incidence and clinical significance of reactive thrombocytosis in children aged 1 to 24 months, hospitalized for community-acquired infections. Platelets 2008, 19, 409–414.
  31. Wang, J.L.; Huang, L.T.; Wu, K.H.; Lin, H.W.; Ho, M.Y.; Liu, H.E. Associations of reactive thrombocytosis with clinical characteristics in pediatric diseases. Pediatr. Neonatol. 2011, 52, 261–266.
  32. Shin, J.; Lee, D.H.; Jung, N.; Choi, H.J.; Shim, Y.J. A cross-sectional retrospective study to analyze the underlying causes and clinical characteristics of children with reactive thrombocytosis at a Korean tertiary medical center. Blood Res. 2018, 53, 233–239.
  33. Thom, C.S.; Echevarria, E.; Osborne, A.D.; Carr, L.; Rubey, K.M.; Salazar, E.; Callaway, D.; Pawlowski, T.; Devine, M.; Kleinman, S.; et al. Extreme thrombocytosis is associated with critical illness and young age, but not increased thrombotic risk, in hospitalized pediatric patients. Thromb. Haemost. 2020, 18, 3352–3358.
  34. Rokkam, V.R.; Kotagiri, R. Secondary Thrombocytosis; StatPearls Publishing: Treasure Island, FL, USA, 2021.
  35. Stockklausner, C.; Duffert, C.M.; Cario, H.; Knöfler, H.; Streif, W.; Kulozik, A.E. Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management. Ann. Hematol. 2021, 100, 1647–1665.
  36. Nigrovic, L.E.; Nigrovic, P.A.; Harper, M.B.; Chiang, V.W. Extreme thrombocytosis predicts Kawasaki disease in infants. Clin. Pediatr. 2006, 45, 446–452.
  37. Baker, R.D.; Greer, F.R.; The Committee on Nutrition. Diagnosis and prevention of iron deficiency and iron deficiency anemia in infants and young children (0–2 years of age). Pediatrics 2010, 126, 1040–1050.
  38. Evstatiev, R.; Bukaty, A.; Jimenez, K.; Kulnigg-Dabschet, S.; Surman, L.; Schmid, W.; Eferl, R.; Lippert, K.; Scheiber-Mojdehkar, B.; Kvasnicka, H.M. Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin. Am. J. Hematol. 2014, 89, 524–529.
  39. Kulnigg-Dabsch, S.; Evstatiev, R.; Dejaco, C.; Gasche, C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS ONE 2012, 7, e34520.
  40. Cerutti, A.; Custodi, P.; Duranti, M.; Cazzola, M.; Balduini, C.L. Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant. Clin. Lab. Haematol. 1999, 2, 271–275.
  41. Bleeker, J.S.; Hogan, W.J. Thrombocytosis: Diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis 2011, 2011, 536062.
  42. Samuk, I.; Seguier-Lipszyc, E.; Baazov, A.; Tamay, H.; Nahum, E.; Steinberg, R.; Freud, E. Emergency or urgent splenectomy in children for non-traumatic reasons. Eur. J. Pediatr. 2019, 178, 1363–1367.
  43. Ianotto, J.C.; Curto-Garcia, N.; Lauermanova, M.; Radia, D.; Kiladjian, J.J.; Harrison, C.N. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: A systematic review. Haematologica 2019, 104, 1580–1588.
  44. Kucine, N. Myeloproliferative neoplasms in children, adolescents, and young adults. Curr. Hematol. Malig. Rep. 2020, 15, 141–148.
  45. Barosi, G.; Tefferi, A.; Besses, C.; Birgegard, G.; Cervantes, F.; Finazzi, G.; Gisslinger, H.; Griesshammer, M.; Harrison, C.; Hehlmann, R.; et al. Clinical end points for drug treatment trials in BCR-ABL negative classic myeloproliferative neoplasms: Consensus statements from the European Leukemia Net (ELN) and International Working Group-Myeloproliferative neoplasms research and treatment. Leukemia 2015, 25, 20–26.
  46. Finazzi, G.; Carobbio, A.; Cervantes, F.; Isola, I.M.; Vannucchi, A.M.; Guglielmelli, P.; Rambaldi, A.; Finazzi, G.; Barosi, G.; Barbui, T. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 2014, 124, 2611–2612.
  47. Tefferi, A.; Guglielmelli, P.; Lasho, T.L.; Coltro, G.; Finke, C.M.; Loscocco, G.G.; Sordi, B.; Szuber, N.; Rotunno, G.; Pacilli, A.; et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br. J. Haematol. 2020, 189, 291–302.
  48. Randi, M.L.; Bertozzi, I.; Putti, M.C. Contemporary management of essential thrombocythemia in children. Expert Rev. Hematol. 2019, 12, 367–373.
  49. Tefferi, A.; Barbui, T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk stratification and management. Am. J. Hematol. 2020, 95, 1599–1613.
  50. Randi, M.L.; Bertozzi, I.; Rumi, E.; Elena, C.; Finazzi, G.; Vianelli, N.; Polverelli, N.; Ruggeri, M.; Vannucchi, A.M.; Antonioli, E.; et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am. J. Hematol. 2014, 89, 306–309.
  51. Landolfi, R.; Marchioli, R.; Kutti, J.; Gisslinger, H.; Tognoni, G.; Patron, C.; Barbui, T. European collaboration on low-dose aspirin in polycythemia vera investigators. Efficacy and safety of low-dose aspirin in Polycythemia vera. N. Engl. J. Med. 2004, 350, 114–124.
  52. Alvarez-Larrán, A.; Pereira, A.; Guglielmelli, P.; Hernández-Boluda, J.C.; Arellano-Rodrigo, E.; Ferrer-Marín, F.; Samah, A.; Griesshammer, M.; Kerguelen, A.; Andreasson, B.; et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 2016, 101, 926–931.
  53. Rocca, B.; Tosetto, A.; Betti, S.; Soldati, D.; Petrucci, G.; Rossi, E.; Timillero, A.; Cavalca, V.; Porro, B.; Iurlo, A.; et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020, 136, 171–182.
  54. Tefferi, A.; Szuber, N.; Pardanani, A.; Hanson, C.A.; Vannucchi, A.M.; Barbui, T.; Gangat, N. Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. Am. J. Hematol. 2021, 96, E182–E184.
  55. Alvarez-Larrán, A.; Sant’Antonio, E.; Harrison, C.; Kiladjian, J.J.; Griesshammer, M.; Mesa, R.; Ianotto, J.C.; Palandri, F.; Hernández-Boluda, J.C.; Birgegård, G.; et al. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: A consensus-based proposal from the European Leukemia Net. Lancet Haematol. 2021, 8, e658–e665.
  56. Hamulyàk, E.N.; Daams, J.G.; Leebeek, F.W.G.; Biemond, B.J.; Bowkhorst, P.A.W.; Middeldorp, S.; Lauw, M.N. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Adv. 2021, 5, 113–121.
  57. Di Nisio, M.; Valeriani, E.; Riva, N.; Schulman, S.; Beyer-Westendorf, J.; Ageno, W. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J. Thromb. Haemost. 2020, 18, 1562–1568.
  58. Tokgoz, H.; Caliskan, U.; Yüksekkaya, H.A.; Kucukkaya, R. Essential thrombocythemia with Mpl W515 K mutation in a child presenting with Budd-Chiari syndrome. Platelets 2015, 26, 805–808.
  59. Wigton, J.C.; Tersak, J.M. JAK2+ Essential thrombocythemia in a young girl with Budd-Chiari syndrome: Diagnostic and therapeutic considerations when adult disease strikes the young. J. Pediatric Hematol. Oncol. 2016, 38, 70–73.
  60. Monagle, P.; Cuello, C.A.; Augustine, C.; Bonduel, M.; Brandão, L.R.; Capman, T.; Chan, A.K.C.; Hanson, S.; Male, C.; Meerpohl, J.; et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: Treatment of pediatric venous thromboembolism. Blood Adv. 2018, 2, 3292–3316.
  61. Young, G.; Lensing, A.W.A.; Monagle, P.; Male, C.; Thelen, K.; Willmann, S.; Palumbo, J.S.; Kumar, R.; Nurmeev, I.; Hege, K.; et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr. phase 3 dose-exposure-response evaluation. J. Thromb. Haemost. 2020, 18, 1672–1685.
  62. Barbui, T. How to manage children and young adults with myeloproliferative neoplasms. Leukemia 2012, 26, 1452–1457.
  63. Harrison, C.N.; Campbell, P.J.; Buck, G.; Wheatley, K.; East, C.L.; Bareford, D.; Wilkins, B.S.; van der Walt, J.D.; Reilly, J.T.; Grigg, A.P.; et al. United Kingdom medical research council primary thrombocythemia 1 study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 2005, 353, 33–45.
  64. Jinna, S.; Khandhar, P.B. Hydroxyurea Toxicity; StatPearls Publishing: Treasure Island, FL, USA, 2021.
  65. Finazzi, G.; Ruggeri, M.; Rodeghiero, F.; Barbui, T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 2003, 101, 37–49.
  66. De Montalembert, M.; Voskaridou, E.; Oevermann, L.; Cannas, G.; Habibi, A.; Loko, G.; Joseph, L.; Colombatti, R.; Bartolucci, P.; Brousse, V.; et al. Real-life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am. J. Hematol. 2021, 96, 1223–1231.
  67. Yacoub, A.; Mascarenhas, J.; Kosiorek, H.; Prchal, J.T.; Berenzon, D.; Baer, M.R.; Ritchie, E.; Silver, R.T.; Kessler, C.; Winton, E.; et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood 2019, 134, 1498–1509.
  68. Quintás-Cardama, A.; Abdel-Wahab, O.; Manshouri, T.; Kilpivaara, O.; Cortes, J.; Roupie, A.L.; Zhang, S.J.; Harris, D.; Estrov, Z.; Kantarjian, H.; et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 2013, 122, 893–901.
  69. Bewersdorf, J.P.; Giri, S.; Wang, R.; Podoltsev, N.; Williams, R.T.; Tallman, M.S.; Rampal, R.K.; Zeidan, A.M.; Stahl, M. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia 2021, 35, 1643–1660.
  70. Masarova, L.; Yin, C.C.; Cortes, J.E.; Konopleva, M.; Bourthakure, G.; Newberry, K.; Kantarjian, H.M.; Bueso-Ramos, C.E.; Verstovsek, S. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp. Hematol. Oncol. 2017, 6, 30.
  71. Pizzi, M.; Silver, R.T.; Barel, A.; Orazi, A. Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod. Pathol. 2015, 28, 1315–1323.
  72. Gugliotta, L.; Tieghi, A.; Tortorella, G.; Scalzulli, P.R.; Ciancia, R.; Lunghi, M.; Cacciola, E.; Cacciola, R.; Candoni, A.; Crugnola, M.; et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk. Res. 2011, 35, 1557–1563.
  73. Gisslinger, H.; Gotic, M.; Holowiecki, J.; Penka, M.; Thiele, J.; Kvasnicka, H.M.; Kralovics, R.; Petrides, P.E.; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET study, a randomized controlled trial. Blood 2013, 121, 1720–1728.
  74. Mazzucconi, M.G.; Baldacci, E.; Latagliata, R.; Breccia, M.; Paoloni, F.; Di Veroli, A.; Cedrone, M.; Anaclerico, B.; Villivà, N.; Porrini, R.; et al. Anagrelide in essential thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1-negative myeloproliferative neoplasms latium group”. Eur. J. Haematol. 2020, 105, 335–343.
  75. Harrison, C.N.; Mead, A.J.; Panchal, A.; Fox, S.; Yap, C.; Gbandi, E.; Houlton, A.; Alimam, S.; Ewing, J.; Wood, M.; et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 2017, 130, 1889–1897.
  76. Zeiser, R.; Polverelli, N.; Ram, R.; Hashmi, S.K.; Chakraverty, R.; Middeke, J.M.; Musso, M.; Giebel, S.; Uzay, A.; Langmuir, P.; et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N. Engl. J. Med. 2021, 385, 228–238.
  77. Loh, M.L.; Tasian, S.K.; Rabin, K.R.; Brown, P.; Magoon, D.; Reid, J.M.; Chen, X.; Ahern, C.H.; Weigel, B.J.; Blaney, S.M. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A children’s oncology group phase 1 consortium study (ADVL1011). Pediatric Blood Cancer 2015, 62, 1717–1724.
  78. Coskun, M.E.; Heigh, S.; Dhawan, A.; Hadzic, N. Ruxolitinib treatment in an infant with JAK2+ polycythemia vera-associated Budd-Chiari syndrome. BMJ Case Rep. 2017, 2017, bcr2017220377.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Hematology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Maria Luigia Randi
View Times: 886
Revisions: 2 times (View History)
Update Date: 24 Jan 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    Academic Video Service
    Feedback